Sulforaphane as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double‐blind, placebo‐controlled clinical trial

Nrf2 activator, sulforaphane ameliorates autism-like symptoms through suppression of Th17 related signaling and rectification of oxidant-antioxidant imbalance in periphery and brain of BTBR T+tf/J mice

(2019) Ahmed Nadeem et al.   BEHAVIOURAL BRAIN RESEARCH

New highlights on the health-improving effects of sulforaphane

(2018) Alfredo Briones-Herrera et al.   Food & Function

Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli

(2018) Stephen Bent et al.   Molecular Autism

Microglia and Autism Spectrum Disorder: Overview of Current Evidence and Novel Immunomodulatory Treatment Options

(2018) Jung Won Kim et al.   Clinical Psychopharmacology and Neuroscience

Isothiocyanate from Broccoli, Sulforaphane, and Its Properties

(2018) Alena Vanduchova et al.   JOURNAL OF MEDICINAL FOOD

Sulforaphane Inhibited the Nociceptive Responses, Anxiety- and Depressive-Like Behaviors Associated With Neuropathic Pain and Improved the Anti-allodynic Effects of Morphine in Mice

(2018) Pablo Ferreira-Chamorro et al.   Frontiers in Pharmacology

Autism Spectrum Disorders — Diagnosis and Management

(2017) Sharmila Banerjee Mukherjee   INDIAN JOURNAL OF PEDIATRICS

The role of oxidative stress, inflammation and acetaminophen exposure from birth to early childhood in the induction of autism

(2017) William Parker et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

Prophylactic effects of sulforaphane on depression-like behavior and dendritic changes in mice after inflammation

(2017) Ji-chun Zhang et al.   JOURNAL OF NUTRITIONAL BIOCHEMISTRY

The Immune System, Cytokines, and Biomarkers in Autism Spectrum Disorder

(2017) Anne Masi et al.   Neuroscience Bulletin

Oxidative Stress and Nitric Oxide in Autism Spectrum Disorder and Other Neuropsychiatric Disorders

(2016) Kunio Yui et al.   CNS & Neurological Disorders-Drug Targets

Neuroinflammation increases GABAergic tone and impairs cognitive and motor function in hyperammonemia by increasing GAT-3 membrane expression. Reversal by sulforaphane by promoting M2 polarization of microglia

(2016) Vicente Hernandez-Rabaza et al.   Journal of Neuroinflammation

Dysregulation of Th1, Th2, Th17, and T regulatory cell-related transcription factor signaling in children with autism

(2016) Sheikh Fayaz Ahmad et al.   MOLECULAR NEUROBIOLOGY

Irritability and Problem Behavior in Autism Spectrum Disorder: A Practice Pathway for Pediatric Primary Care

(2016) K. McGuire et al.   PEDIATRICS

Inflammatory Cytokines: Potential Biomarkers of Immunologic Dysfunction in Autism Spectrum Disorders

(2015) Ningan Xu et al.   MEDIATORS OF INFLAMMATION

Oxidative stress as an etiological factor and a potential treatment target of psychiatric disorders. Part 2. Depression, anxiety, schizophrenia and autism

(2015) Irena Smaga et al.   Pharmacological Reports

A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: Effects on aberrant behavior in children with autism

(2015) Ali Ghaleiha et al.   PSYCHIATRY RESEARCH

Drug therapy in autism: a present and future perspective

(2014) Baldeep Kumar et al.   Pharmacological Reports

Sulforaphane treatment of autism spectrum disorder (ASD)

(2014) K. Singh et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The epidemiology and global burden of autism spectrum disorders

(2014) A. J. Baxter et al.   PSYCHOLOGICAL MEDICINE

World Medical Association Declaration of Helsinki

(2013)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients

(2013) Nazila Shahmansouri et al.   JOURNAL OF AFFECTIVE DISORDERS

Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial

(2013) Ali Ghaleiha et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Riluzole as an Adjunctive Therapy to Risperidone for the Treatment of Irritability in Children with Autistic Disorder: A Double-Blind, Placebo-Controlled, Randomized Trial

(2013) Ali Ghaleiha et al.   PEDIATRIC DRUGS

Effect of Nrf2 activators on release of glutathione, cysteinylglycine and homocysteine by human U373 astroglial cells

(2013) Megan L. Steele et al.   Redox Biology

Autism spectrum disorders

(2012) Alexis Tchaconas et al.   CURRENT OPINION IN PEDIATRICS

Oral Scopolamine Augmentation in Moderate to Severe Major Depressive Disorder

(2012) Danial Khajavi et al.   JOURNAL OF CLINICAL PSYCHIATRY

Celecoxib as adjunctive treatment to risperidone in children with autistic disorder: a randomized, double-blind, placebo-controlled trial

(2012) Mahtab Asadabadi et al.   PSYCHOPHARMACOLOGY

Psychoneuroimmunology Meets Neuropsychopharmacology: Translational Implications of the Impact of Inflammation on Behavior

(2011) Ebrahim Haroon et al.   NEUROPSYCHOPHARMACOLOGY

Nutritional and metabolic status of children with autism vs. neurotypical children, and the association with autism severity

(2011) James B Adams et al.   Nutrition & Metabolism

Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome

(2010) Paul Ashwood et al.   BRAIN BEHAVIOR AND IMMUNITY

Defining the cognitive phenotype of autism

(2010) T. Charman et al.   BRAIN RESEARCH

Elevated immune response in the brain of autistic patients

(2009) Xiaohong Li et al.   JOURNAL OF NEUROIMMUNOLOGY

Double-blind placebo-controlled trial of pentoxifylline added to risperidone: Effects on aberrant behavior in children with autism

(2009) Shahin Akhondzadeh et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Modafinil as a treatment for Attention-Deficit/Hyperactivity Disorder in children and adolescents: A double blind, randomized clinical trial

(2007) Shahrokh Amiri et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY